Skandinaviska Enskilda Banken AB publ Has $2.74 Million Holdings in Halozyme Therapeutics, Inc. $HALO

Skandinaviska Enskilda Banken AB publ decreased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 26.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 37,300 shares of the biopharmaceutical company’s stock after selling 13,700 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Halozyme Therapeutics were worth $2,736,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HALO. DLD Asset Management LP acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth about $650,250,000. Arrowstreet Capital Limited Partnership boosted its stake in Halozyme Therapeutics by 127.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock worth $132,192,000 after acquiring an additional 1,425,674 shares during the last quarter. Federated Hermes Inc. grew its holdings in Halozyme Therapeutics by 294.1% during the third quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock valued at $106,395,000 after purchasing an additional 1,082,638 shares during the period. LSV Asset Management increased its stake in Halozyme Therapeutics by 0.9% in the third quarter. LSV Asset Management now owns 1,266,027 shares of the biopharmaceutical company’s stock valued at $92,850,000 after purchasing an additional 10,787 shares in the last quarter. Finally, Royal London Asset Management Ltd. increased its stake in Halozyme Therapeutics by 122.3% in the second quarter. Royal London Asset Management Ltd. now owns 1,101,912 shares of the biopharmaceutical company’s stock valued at $57,321,000 after purchasing an additional 606,236 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $70.98 on Friday. The company has a fifty day moving average price of $72.14 and a 200 day moving average price of $70.36. The firm has a market cap of $8.38 billion, a PE ratio of 28.51, a PEG ratio of 0.29 and a beta of 0.97. The company has a current ratio of 4.66, a quick ratio of 1.37 and a debt-to-equity ratio of 43.89. Halozyme Therapeutics, Inc. has a 1-year low of $47.50 and a 1-year high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $1.92 by ($2.16). The firm had revenue of $451.77 million during the quarter, compared to analyst estimates of $446.13 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The business’s revenue for the quarter was up 51.6% compared to the same quarter last year. During the same period in the prior year, the business earned $1.26 EPS. Research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on HALO shares. The Goldman Sachs Group reissued a “sell” rating and set a $56.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Wall Street Zen downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday. TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday. Wells Fargo & Company increased their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday. Finally, Benchmark raised their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $78.56.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total value of $1,522,400.00. Following the sale, the chief executive officer directly owned 708,719 shares in the company, valued at $53,947,690.28. This trade represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $70.25, for a total transaction of $140,500.00. Following the transaction, the director owned 40,123 shares of the company’s stock, valued at $2,818,640.75. The trade was a 4.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 49,398 shares of company stock valued at $3,650,592 over the last ninety days. Company insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.